{
    "organizations": [],
    "uuid": "aeccd0c320bcf67e7a14bb91d4299e34f0c59394",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-idera-pharma-announces-launch-of-p/brief-idera-pharma-announces-launch-of-phase-3-trial-evaluating-imo-2125-in-combination-with-ipilimumab-idUSASB0C896",
    "ord_in_thread": 0,
    "title": "Idera Pharma Announces Launch Of Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Idera Pharmaceuticals Inc:\n* IDERA PHARMACEUTICALS ANNOUNCES LAUNCH OF GLOBAL PHASE 3 TRIAL EVALUATING IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ANTI-PD-1 REFRACTORY MELANOMA (ILLUMINATE 301) Source text for Eikon: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-01T20:13:00.000+02:00",
    "crawled": "2018-03-02T19:41:33.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "idera",
        "pharmaceutical",
        "inc",
        "idera",
        "pharmaceutical",
        "announces",
        "launch",
        "global",
        "phase",
        "trial",
        "evaluating",
        "combination",
        "ipilimumab",
        "treatment",
        "refractory",
        "melanoma",
        "illuminate",
        "source",
        "text",
        "eikon"
    ]
}